Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 11:11:599602.
doi: 10.3389/fonc.2021.599602. eCollection 2021.

The Prognostic Value of Plasma Cell-Free DNA Concentration in the Prostate Cancer: A Systematic Review and Meta-Analysis

Hongtao Liu  1   2 , Yuzhen Gao  3 , Somayeh Vafaei  4 , Xiao Gu  2   5 , Xiaoli Zhong  3   5
Affiliations

The Prognostic Value of Plasma Cell-Free DNA Concentration in the Prostate Cancer: A Systematic Review and Meta-Analysis

Hongtao Liu et al. Front Oncol. .

Abstract

Objective: By virtue of largely disparate clinical outcomes of prostate cancer (PCA), there is a pressing need to search for useful biomarkers for PCA prognosis. Cell-free DNA (cfDNA) is a promising biomarker for detecting, monitoring, and predicting survival of prostate cancer (PCA). However, the utility of total cfDNA quantitation in PCA in clinical setting remains elusive. Here, we performed a thorough meta-analysis to assess the prognostic value of cfDNA concentration for patients with PCA. In addition, we tested the possibility of the combination of PSA and cfDNA test results to improve the prediction power in PCA prognosis.

Method and materials: More than six databases, including PubMed, Web of Science, Medline, PMC, EMBASE and the Cochrane Library were searched. Results yielded all eligible articles from the date of inception to June 30, 2020. Continuous, diagnostic, and prognostic variables in cfDNA in PCA were included in the meta-analysis by STATA.

Results: A total of 23 articles were enrolled in our meta-analysis: 69.6% (16/23) were related to diagnosis, and 56.5% (13/23) were related to prognosis. The pooled concentration of cfDNA in PCA patients was significantly higher than in the control group (SMD = 0.89, 95%CI = 0.53, 1.26), mirroring results for the prostate-specific antigen (PSA). For the detection test variables, the SROC with 95%CI was 0.87 (0.84-0.90) for cfDNA concentration. In terms of prognostic variables, the concentrations of cfDNA were significantly related with progression-free survival (PFS, logHR = 0.84 (95%CI0.39, 1.28) and overall survival [OS, log HR = 0.60 (95%CI0.29, 0.90)]. Lastly, the test showed no significant publication bias in the present meta-analysis, excluding the diagnostic meta-analysis.

Conclusions: The concentration of cell-free DNA is high in the prostate cancer patients. The present study substantiates the prognostic value of the cfDNA concentration. High concentration cfDNA correlates with poor disease outcome of CRPC. The study cohort with large sample size is needed to evaluate the prognosis value of cfDNA in the future. We also emphasized that combination of PSA and cf DNA quantitation is important in future large individual meta study.

Keywords: cell-free DNA; diagnosis; meta-analysis; prognosis; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study inclusion and exclusion for meta-analysis.
Figure 2
Figure 2
The heterogeneity of cfDNA and PSA values between the PCA and control group (cfDNA, cell free DNA; PSA, prostate-specific antigen.) (A): Forest plots of the concentration of cfDNA; (B): Forest plots of PSA; (C): Correlation between cfDNA and PSA in Alexander’s and Vandekerkhov’s article.
Figure 3
Figure 3
Prognostic value of cfDNA in prostate cancer. (A): Forest plots for PFS; (B): Forest plots for PFS in CRPC (Castration-Resistant Prostate Cancer); (C): Forest plots for OS; (D): Forest plots for OS in CRPC.
Figure 4
Figure 4
The prognosis value of PSA, cfDNA and the combination of them in the Torquato’s cohort. (A): PSA for PFS; (B): CfDNA for PFS; (C): PSA + cfDNA for PFS; (D): Time-dependent ROC of them for predicting PFS; (E): PSA for OS; (F): CfDNA for OS; (G): PSA + cfDNA for OS; (H): Time-dependent ROC of them for predicting OS.
Figure 5
Figure 5
The assessment of potential publication bias in the meta-analysis. (A): The Begg’s test for the pooled results of difference between two groups. (B) The Deek’s test for the diagnostic meta-analysis. (C): The Begg’s test for the progression free survival meta-analysis.; (D): The Begg’s test for the overall survival meta-analysis; (E): The Begg’s test for the progression free survival meta-analysis in CRPC; (F): The Begg’s test for the overall survival meta-analysis in CRPC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med (1993) 118(10):804–18. 10.7326/0003-4819-118-10-199305150-00008 - DOI - PubMed
    1. Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol (2018) 200(6):1264–72. 10.1016/j.juro.2018.07.090 - DOI - PubMed
    1. Fallowfield L, Payne H, Jenkins V. Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2016) 13(10):643–50. 10.1038/nrclinonc.2016.100 - DOI - PubMed
    1. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA (2018) 319(18):1914–31. 10.1001/jama.2018.3712 - DOI - PubMed
    1. Crawford ED, Rove KE, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky KC, et al. . Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol (2012) 188(5):1726–31. 10.1016/j.juro.2012.07.023 - DOI - PubMed

Publication types